Cabaletta Bio director granted options on 22,000 shares

Cabaletta Bio, Inc. director Richard C. Henriques Jr. received a grant of stock options covering 22,000 shares of common stock.

Rhea-AI Filing Summary

Cabaletta Bio, Inc. director Richard C. Henriques Jr. received a grant of stock options covering 22,000 shares of common stock. The options have an exercise price of $3.22 per share and expire on June 8, 2036. They will vest in full on the earlier of June 9, 2027 or the date of the company’s next annual stockholder meeting.

Insider Trade Summary

Grant/Award: 22,000 shares

Grant/Award 1 txn

Insider HENRIQUES RICHARD C JR

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	22,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 22,000 contracts (Direct)

Footnotes (1)

1. F1. This option shall vest in full upon the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of the Corporation's stockholders.

Key Figures

Option grant size: 22,000 shares Exercise price: $3.22 per share Expiration date: June 8, 2036 +2 more

5 metrics

Option grant size 22,000 shares Stock Option (Right to Buy) covering common stock

Exercise price $3.22 per share Conversion or exercise price of stock option

Expiration date June 8, 2036 Option expiration date

Underlying shares 22,000 shares Underlying common stock for the option

Vesting trigger date June 9, 2027 Latest vesting date; earlier vesting at next annual meeting

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, underlying security, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 3.2200"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-08T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

underlying security financial

"underlying_security_title: Common Stock"

vest in full financial

"This option shall vest in full upon the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Cabaletta Bio (CABA) disclose in this Form 4 filing?

Cabaletta Bio reported that director Richard C. Henriques Jr. received a stock option grant for 22,000 shares of common stock at an exercise price of $3.22 per share, expiring June 8, 2036, as part of his equity compensation.

How many Cabaletta Bio (CABA) shares are covered by the new option grant?

The new option grant covers 22,000 shares of Cabaletta Bio common stock. These options give the director the right to buy those shares at $3.22 per share if and when they vest and are exercised before their June 8, 2036 expiration date.

What is the exercise price of the Cabaletta Bio (CABA) stock options granted?

The exercise price of the granted stock options is $3.22 per share. This means the director can purchase up to 22,000 shares of Cabaletta Bio common stock at $3.22 if he chooses to exercise the options after they vest and before expiration.

When do the Cabaletta Bio (CABA) stock options granted to the director vest?

The options vest in full on the earlier of June 9, 2027 or the date of Cabaletta Bio’s next annual meeting of stockholders. Full vesting means the director can then exercise all 22,000 options at the $3.22 per share exercise price.

Did the Cabaletta Bio (CABA) director buy or sell shares in the market?

The filing reports a grant of stock options, not an open-market trade. The director received 22,000 options as compensation with a $3.22 exercise price, expiring June 8, 2036, and no market purchase or sale of common shares is disclosed here.

What is the expiration date of the Cabaletta Bio (CABA) stock options granted?

The granted stock options expire on June 8, 2036. If the director does not exercise the options to buy up to 22,000 Cabaletta Bio common shares at $3.22 per share by that date, the options will lapse and become worthless.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/10/2026 - 06:56 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HENRIQUES RICHARD C JR

(Last) (First) (Middle)

C/O CABALETTA BIO, INC.

2929 ARCH STREET, SUITE 600

(Street)

PHILADELPHIA PENNSYLVANIA 19104

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cabaletta Bio, Inc. [ CABA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.22	06/09/2026		A		22,000		(1)	06/08/2036	Common Stock	22,000	$0	22,000	D

Explanation of Responses:

1. This option shall vest in full upon the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of the Corporation's stockholders.

	/s/ Michael Gerard, Attorney-in-Fact	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)